CT影像组学预测HER2阳性可手术切除进展期胃癌结局的初步研究
该回顾性多中心研究纳入621例HER2阳性可手术切除进展期胃癌患者,构建结合Radscore与临床评分的CT影像组学模型预测总生存,模型在训练、内部验证和外部验证队列的C-index分别为0.711、0.669和0.693,优于临床评分、pTNM和cTNM,但劣于ypTNM,且可为pTNM提供增量价值。
要点
- CT影像组学模型可对HER2阳性可手术切除进展期胃癌进行风险分层,区分高、低风险组。
- 模型预测总生存的C-index在训练集为0.711,内部验证0.669,外部验证0.693。
- 模型优于临床评分、pTNM和cTNM,但劣于ypTNM,且可为pTNM提供增量预后价值。
核心结论
- CT影像组学模型可对HER2阳性可手术切除进展期胃癌进行个体化预后预测,在预测总生存方面优于临床评分、pTNM和cTNM,并为pTNM带来增量获益,在不同患者类型中表现出一定普适性。
研究设计与样本
- 回顾性研究,纳入两家医院621例接受根治性胃切除术或新辅助治疗/化疗后根治性胃切除术的HER2阳性可手术切除进展期胃癌患者,分为训练队列(n=330)、内部验证队列(n=143)和外部验证队列(n=148),构建结合Radscore与临床评分的影像组学模型,采用Kaplan-Meier估计、Log-rank检验和Harrell C-index评估模型性能。
诊断标准与关键数值
- 影像组学模型预测总生存的C-index:训练队列0.711(95%CI 0.666-0.756;p<0.001)、内部验证队列0.669(95%CI 0.585-0.753;p=0.009)、外部验证队列0.693(95%CI 0.597-0.789;p=0.015);模型在所有队列中成功将患者分为高风险组和低风险组。
临床应用与阅片要点
- 作者认为该影像组学模型可提供HER2阳性可手术切除进展期胃癌的个体化预后预测,并可为pTNM提供增量价值,但模型劣于ypTNM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Accurate risk stratification in human epidermal growth factor receptor 2-positive surgically resectable advanced gastric cancer (HER2-p SRAGC) can strengthen monitoring for high-risk patients, allowing timely HER2-specific treatment and potentially improving prognosis. Therefore, we aimed to develop a CT radiomics model for predicting outcomes in HER2-p SRAGC and compare it with the 8th edition TNM staging system.
MATERIALS AND METHODS: 621 HER2-p SRAGC patients who received either radical gastrectomy or radical gastrectomy after neoadjuvant therapy or chemotherapy were retrospectively enrolled in two hospitals and assigned to a training (n=330), an internal validation (n=143) and an external validation (n=148) cohorts. A radiomics model incorporating Radscore and clinical scores was constructed. Model performance was assessed by Kaplan-Meier estimator, Log-rank test, and Harrell's C-index.
RESULTS: The radiomics model was correlated with the overall survival (OS) across all cohorts, with C-indexes of 0.711[95% confidence interval (CI): 0.666-0.756; p<0.001; training], 0.669 (95%CI: 0.585-0.753; p=0.009; internal validation) and 0.693 (95%CI: 0.597-0.789; p=0.015; external validation). In all study cohorts, the radiomics model successfully stratified patients into high-risk and low-risk groups, and outweighed individual scores, pathological staging (pTNM), and clinical staging (cTNM) but was inferior to post-neoadjuvant therapy staging (ypTNM). Additionally, the radiomics model had added value to the prognostic efficacy of pTNM and was unaffected by patient age and gender.
CONCLUSION: The radiomics model delivers individualized prognosis prediction of HER2-p SRAGC, surpassing clinical scores, and both pTNM and cTNM in forecasting OS. It confers incremental benefit to pTNM and exhibits certain universality across patient types.
TRIAL REGISTRATION: Retrospectively registered.
引用
- Zhao H, Gao J, Li J, et al. CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study. Acad Radiol. 2025. PMID: 40461325. doi:10.1016/j.acra.2025.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。